Articles From: Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference to Verenium Corporation to Announce First Quarter 2013 Financial Results


2013/2/11
NEW YORK, Feb.
Sign-up for Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference investment picks
2013/5/17
SAN DIEGO and NEW YORK, May 17, 2013 /PRNewswire/ --  Shareholder rights attorneys at Robbins Arroyo LLP announce that a shareholder of Ventrus Biosciences, Inc. (NASDAQ: VTUS) filed a federal securities fraud class action complaint on May 9, 2013 , in the U.S. District Court for the Southern District of New York.
Sign-up for Ventrus Biosciences, Inc. Sued by Investor investment picks
2013/2/7
Veolia Energy North America , a leading operator and developer of efficient energy solutions, today announced the completion and commissioning of two new, natural gas-fired rapid-response boilers, as part of the company’s recently extended steam supply agreement with the University of Pennsylvania (Penn). The rapid-response boilers replace an older, less-efficient oil-fired boiler, increasing the overall efficiency of Veolia Energy’s steam service in the central business and university city districts of Philadelphia, and significantly reducing greenhouse gas emissions.
Sign-up for Veolia Energy Joins with Penn to Support the University’s Climate Action Plan investment picks
2013/3/6
Veolia Water North America (Veolia Water), the nation’s leading provider of municipal and industrial water and wastewater partnerships, significantly outperformed public municipal systems as well as private-industry water, wastewater and other comparable utility systems, in the area of safety for the sixth year in a row as compared to the most recent data available from the Bureau of Labor Statistics (BLS). In 2012, approximately 98 percent of all Veolia Water’s facilities marked no lost-time milestones ranging from one year to 27 years.
Sign-up for Veolia Water North America Safety Performance Surpasses Municipal and Private Sector for Sixth Year in a Row investment picks
2013/1/30
Awards recognize dedication to safety and environmental excellence BOSTON , Jan.
Sign-up for Veolia Water Takes Home Four Awards at the New England Water Environment Association Conference investment picks
2013/4/29
Dalkia , a joint venture of French utilities Veolia Environnement (VIE.FR) and Electricite de France SA (EDF.FR), Monday said it renewed a contract to manage heat generation distribution in a district of Slovakia's capital, Bratislava , for an additional 20 years.
Sign-up for Veolia's Dalkia Renews EUR1 Billion Contract in Slovakia investment picks
2013/3/13
Fourth quarter net revenues increased 21% to $162.6 million; Direct net revenues increased 27% and Indirect net revenues increased 11%. Diluted EPS were $0.62 for the fourth quarter, compared to $0.50 for the same quarter of fiscal 2012, an increase of 24%. Full year net revenues increased 17% to $541.1 million; Direct net revenues increased 30% and Indirect net revenues increased 6%. Diluted EPS were $1.70 for fiscal 2013, compared to $1.43 for fiscal 2012, an increase of 19%. FORT WAYNE, Ind., March 13, 2013 (GLOBE NEWSWIRE) -- Vera Bradley, Inc. (Nasdaq:VRA) today announced its financial results for the fourth quarter and fiscal year, representing the 14-week and 53-week periods ended February 2, 2013.
Sign-up for Vera Bradley Announces Fourth Quarter and Fiscal Year 2013 Results investment picks
2013/3/26
FORT WAYNE, Ind., March 26, 2013 (GLOBE NEWSWIRE) -- Vera Bradley, Inc. (Nasdaq:VRA) announced today that the company will be presenting at the 5 th Annual TAG Spring Consumer Conference held at the InterContinental Hotel New York Times Square in New York City on Tuesday, April 9, 2013 at 1:10 pm Eastern Time.
Sign-up for Vera Bradley Announces Participation in the 5th Annual TAG Spring Consumer Conference investment picks
2013/2/27
FORT WAYNE, Ind., Feb.
Sign-up for Vera Bradley Announces Reporting Date for Fiscal Year 2013 Fourth Quarter Results investment picks
2013/3/11
FORT WAYNE, Ind., March 11, 2013 (GLOBE NEWSWIRE) -- Vera Bradley, Inc. (Nasdaq:VRA) today announced it has further enhanced its executive team with the appointment of Bonita Inza as EVP, Sales & Marketing - Chief Experience Officer, a newly created position.
Sign-up for Vera Bradley Appoints EVP of Sales & Marketing - Chief Experience Officer investment picks
2013/3/13
Verastem, Inc., (NASDAQ: VSTM) , a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that financial results for the year ended December 31, 2012, will be released before the market opens on Wednesday, March 27, 2013.
Sign-up for Verastem Announces Timing for Year-End 2012 Financial Results, Webcast and Conference Call investment picks
2013/2/27
Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that Robert Weinberg, Ph.D., Verastem scientific cofounder and chair of the Scientific Advisory Board, and Christoph Westphal, M.D., Ph.D., Verastem cofounder, Chairman and CEO, will present at the MIT Technology Breakfast on February 28, 2013, at 8am ET.
Sign-up for Verastem Cofounders to Present at MIT Technology Breakfast on Breakthrough Discoveries in Cancer Stem Cells investment picks
2013/2/5
Verastem, Inc., (NASDAQ: VSTM) , a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer.
Sign-up for Verastem Initiates Phase 1/1b Clinical Trial of VS-6063 Plus Paclitaxel for Patients with Ovarian Cancer investment picks
2013/5/9
Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the quarter ended March 31, 2013, and also commented on certain corporate accomplishments and plans.
Sign-up for Verastem Reports First Quarter 2013 Financial and Corporate Results investment picks
2013/3/27
Verastem, Inc., (NASDAQ: VSTM) , a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, reported financial results for the year ended December 31, 2012, and also commented on corporate accomplishments and plans.
Sign-up for Verastem Reports Year-End 2012 Financial Results investment picks
2013/2/20
Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of data at the Keystone Symposia on “PI3-Kinase and Interplay with Other Signaling Pathways” being held February 24 – March 1, 2013, in Keystone, Colorado.
Sign-up for Verastem to Present at Keystone Symposia on PI3 Kinase investment picks
2013/2/4
Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences.
Sign-up for Verastem to Present at Upcoming Conferences investment picks
2013/2/26
Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences.
Sign-up for Verastem to Present at Upcoming Conferences investment picks
2013/3/28
Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences.
Sign-up for Verastem to Present at Upcoming Conferences investment picks
2013/4/17
Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences.
Sign-up for Verastem to Present at Upcoming Conferences investment picks
2013/5/8
Verastem, Inc., (NASDAQ: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences.
Sign-up for Verastem to Present at Upcoming Conferences investment picks
2013/4/3
Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of preclinical data at the American Association for Cancer Research annual meeting being held April 6 - 10, 2013, at the Walter E.
Sign-up for Verastem to Present Scientific Results at the 2013 AACR Annual Meeting investment picks
2013/2/19
http://media.marketwire.com/attachments/201212/111772_verdelogocopy.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=987176&ProfileId=051205&sourceType=1 BOSTON, MA --
Sign-up for Verde Media Group Announces That "Winter's Wind" Is Coming to Showcase Cinemas in Massachusetts investment picks
2013/2/13
http://media.marketwire.com/attachments/201212/111772_verdelogocopy.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=985273&ProfileId=051205&sourceType=1 LOS ANGELES, CA --
Sign-up for Verde Media Group Inc. Announces Launch Of Tixbeast.com investment picks
2013/2/12
http://media.marketwire.com/attachments/201212/111772_verdelogocopy.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=984531&ProfileId=051205&sourceType=1 LOS ANGELES, CA --
Sign-up for Verde Media Group Inc. Has Partnered With Coldsmoke Film as the Media Sponsor for the Coldsmoke Awards investment picks
2013/4/10
http://media.marketwire.com/attachments/201207/66682_logostm.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1005685&ProfileId=051205&sourceType=1 SINGAPORE --
Sign-up for Veredus Laboratories Confirms VereFlu(TM) Lab-on-Chip Detects the Current Subtype of Avian Flu H7N9 in Addition to All Other Human Flu Subtypes investment picks
2013/2/4
--High-performance, eco-friendly next-generation enzyme now available for the oil and gas industry-- --Verenium to exhibit at the Society of Petroleum Engineers Hydraulic Fracturing Technology Conference February 4th - 6th--
Sign-up for Verenium Announces Commercial Launch Of Pyrolase® HT Product investment picks
2013/3/14
-- Revenue and product gross profit expected to exceed 2012 guidance -- --
Sign-up for Verenium Announces Preliminary Financial Results For Fiscal 2012 investment picks
2013/2/26
-- Adds strong global commercial operations experience --
Sign-up for Verenium Appoints Holger Liepmann To Its Board Of Directors investment picks
2013/5/2
SAN DIEGO , May 2, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM) , a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release first quarter 2013 financial results on Thursday, May 9, 2013 after market close.
Sign-up for Verenium Corporation to Announce First Quarter 2013 Financial Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Ventrus Biosciences to Present at the Leerink Swann Global Healthcare Conference to Verenium Corporation to Announce First Quarter 2013 Financial Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity